Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Genus (GNS) Share Price

Price 2,995.00p on 03-02-2026 at 10:39:48
Change 30.00p 1.01%
Buy 3,000.00p
Sell 2,990.00p
Last Trade: Sell 18.00 at 2,995.00p
Day's Volume: 16,182
Last Close: 2,965.00p
Open: 3,040.00p
ISIN: GB0002074580
Day's Range 2,965.00p - 3,040.00p
52wk Range: 1,548.00p - 3,220.00p
Market Capitalisation: £1.99b
VWAP: 2,989.70863p
Shares in Issue: 66.41m

Genus (GNS) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 18 2,995.00p Automatic Execution
10:39:48 - 03-Feb-26
Sell* 2 2,995.00p Automatic Execution
10:39:48 - 03-Feb-26
Sell* 8 2,995.00p Automatic Execution
10:39:48 - 03-Feb-26
Sell* 33 2,995.00p Automatic Execution
10:39:48 - 03-Feb-26
Sell* 19 2,995.00p Automatic Execution
10:39:48 - 03-Feb-26
Sell* 34 2,995.00p Automatic Execution
10:39:48 - 03-Feb-26
Sell* 75 2,995.00p Automatic Execution
10:39:48 - 03-Feb-26
Sell* 50 2,995.00p Automatic Execution
10:39:48 - 03-Feb-26
Sell* 25 2,995.00p Automatic Execution
10:39:48 - 03-Feb-26
Sell* 2 2,995.00p Automatic Execution
10:38:36 - 03-Feb-26
See more Genus trades

Genus (GNS) Share Price History

Time period:
to
Date Open High Low Close Volume
3rd Feb 2026 (Tue) 3,040.00 3,040.00 2,965.00 2,965.00 16,182
2nd Feb 2026 (Mon) 3,170.00 3,175.00 2,965.00 2,965.00 435,169
30th Jan 2026 (Fri) 3,025.00 3,170.00 3,025.00 3,160.00 415,661
29th Jan 2026 (Thu) 3,020.00 3,055.00 2,990.00 3,055.00 191,740
28th Jan 2026 (Wed) 2,955.00 3,035.00 2,955.00 3,035.00 234,274
27th Jan 2026 (Tue) 2,900.00 2,985.00 2,875.00 2,970.00 354,288
26th Jan 2026 (Mon) 2,845.00 2,905.00 2,805.00 2,895.00 443,325
23rd Jan 2026 (Fri) 2,865.00 2,865.00 2,765.00 2,815.00 52,804
22nd Jan 2026 (Thu) 2,830.00 2,850.00 2,775.00 2,800.00 73,926
21st Jan 2026 (Wed) 2,780.00 2,805.00 2,700.00 2,800.00 59,852
20th Jan 2026 (Tue) 2,795.00 2,795.00 2,740.00 2,765.00 54,184
19th Jan 2026 (Mon) 2,800.00 2,900.00 2,800.00 2,835.00 123,016
16th Jan 2026 (Fri) 3,020.00 3,035.00 2,745.00 2,835.00 330,027
15th Jan 2026 (Thu) 2,585.00 2,630.00 2,555.00 2,630.00 184,378
14th Jan 2026 (Wed) 2,520.00 2,610.00 2,500.00 2,595.00 359,349
13th Jan 2026 (Tue) 2,560.00 2,570.00 2,510.00 2,515.00 62,724
12th Jan 2026 (Mon) 2,495.00 2,580.00 2,495.00 2,565.00 1,517,207
9th Jan 2026 (Fri) 2,570.00 2,570.00 2,535.00 2,540.00 77,835
8th Jan 2026 (Thu) 2,615.00 2,635.00 2,545.00 2,565.00 243,059
7th Jan 2026 (Wed) 2,610.00 2,655.00 2,580.00 2,635.00 74,546
6th Jan 2026 (Tue) 2,575.00 2,575.00 2,490.00 2,575.00 68,726
5th Jan 2026 (Mon) 2,565.00 2,580.00 2,515.00 2,525.00 74,199
See more Genus price history

Genus (GNS) Regulatory News

Date Source Headline
2nd Feb 2026 12:39 pm RNS Block Listing Return
2nd Feb 2026 11:21 am RNS Total Voting Rights
2nd Feb 2026 7:00 am RNS Successful formation of Chinese porcine JV
23rd Jan 2026 5:23 pm RNS PRP Regulatory Progress – Canada
16th Jan 2026 7:00 am RNS Half Year Trading Update – Ahead of expectations
27th Nov 2025 7:00 am RNS Director/PDMR Shareholding
19th Nov 2025 12:12 pm RNS Results of AGM
19th Nov 2025 7:00 am RNS Non-Executive Director Appointments
19th Nov 2025 7:00 am RNS AGM Trading Update
3rd Nov 2025 10:56 am RNS Total Voting Rights
See more Genus regulatory news

Genus (GNS) Share News

Genus completes formation of Chinese porcine joint venture

2nd Feb 2026 12:42

(Alliance News) - Genus PLC on Monday said it has successfully formed its Chinese porcine joint venture, seeing the move as the "the best platform" to drive growth at PIC China. Read More

LONDON BRIEFING: UK house price growth rises; AstraZeneca joins NYSE

2nd Feb 2026 07:56

(Alliance News) - UK annual house price growth rises more than expected in January, while AstraZeneca starts trading in New York and FitzWalter Capital says it does not intend to make an offer for Auction Technology Group. Read More

LONDON BRIEFING: GSK wins EU nod for RSV shot; Spire in early talks

26th Jan 2026 07:59

(Alliance News) - GSK wins EU approval to expand use of its RSV vaccine Arexvy to all adults over 18, while Grainger unveils plans for a 195-home West London development, and Impax Environmental Markets outlines its tender offer plan amid continued pressure from activist investor Saba. Read More

IN BRIEF: Genus says PRRS resistant pig gene edit approved in Canada

26th Jan 2026 06:57

Genus PLC - Basingstoke, England-based animal biotechnology and genetics - Says government approves the use of its gene edit for pigs, which provides resistance to a global disease. Porcine reproductive and respiratory syndrome causes suffering and premature death to pigs, with Genus noting a study that estimated the cost of PRRS at USD1.2 billion per year in the US alone. The approval of the PRRS resistant pig programme follows years of work with multiple Canadian regulators, Genus says, and is an important step toward commercialisation in North America. Genus is seeking approval for the PRP gene edit in key North American export markets such as Mexico and Japan, as well as in China. Read More

LONDON BROKER RATINGS: Goldman Sachs ups targets for Schroders, LSEG

19th Jan 2026 09:45

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More

See more Genus news
FTSE 100 Latest
Value10,325.27
Change-16.29

Login to your account

Forgot Password?

Not Registered